利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.026 秒)

    Formulation for administration of steroid compounds
    1.
    发明授权
    Formulation for administration of steroid compounds 失效
    类固醇化合物的给药配方

    公开(公告)号：US5824668A

    公开(公告)日：1998-10-20

    申请号：US744979

    申请日：1996-11-07

    申请人： Joseph Rubinfeld ,  Julius A. Vida ,  H. Leon Bradlow ,  Elliott L. Fineman

    发明人： Joseph Rubinfeld ,  Julius A. Vida ,  H. Leon Bradlow ,  Elliott L. Fineman

    IPC分类号： A61K9/00 ,  A61K31/565 ,  A61K47/40 ,  A61K47/48 ,  A61K31/56

    CPC分类号： A61K31/5685 ,  A61K31/565 ,  A61K47/40 ,  A61K47/48969 ,  A61K9/0019 ,  B82Y5/00 ,  Y10S514/814 ,  Y10S514/866 ,  Y10S514/909

    摘要： Disclosed are compositions including at least one 5.beta. steroid and an amorphous cyclodextrin. Also disclosed are methods for treating a condition such as obesity, diabetes syndrome, diabetes-associated hypercorticoidism, combinations thereof, and anemic disorders by administering to a mammal in need of such treatment a composition including an obesity-, diabetes-, or anemia antagonistic amount of at least one 5.beta. steroid and an amorphous cyclodextrin. Furthermore, disclosed are methods for treating a subject for a condition that responds to treatment with DHEA by administering to the subject at least one 5.beta. steroid and DHEA in an amount that minimizes the contribution of the DHEA to the production of testosterone and estradiol while maximizing an amount of .alpha.ET and .beta.ET circulating in the subject's blood from an initial dose administered to the subject.

    摘要翻译： 公开了包含至少一种5β类固醇和无定形环糊精的组合物。 还公开了通过向需要这种治疗的哺乳动物施用包括肥胖症，糖尿病或贫血拮抗剂量的组合物来治疗诸如肥胖症，糖尿病综合征，糖尿病相关性高糖皮质激素，其组合和贫血性疾病的病症的方法 的至少一种5β类固醇和无定形环糊精。 此外，所公开的方法是用于通过向受试者施用至少一种5β类固醇和DHEA以使DHEA对产生睾酮和雌二醇的贡献最小化的量给予受试者来治疗受试者的病症。 从受试者的初始剂量中流出的受试者血液中的αET和βET的量。

    Liposome formulation of 5 &bgr; steroids
    2.
    发明授权
    Liposome formulation of 5 &bgr; steroids 失效
    5β类固醇的脂质体制剂

    公开(公告)号：US06436435B1

    公开(公告)日：2002-08-20

    申请号：US09300819

    申请日：1999-04-27

    申请人： Joseph Rubinfeld ,  Elliott L. Fineman

    发明人： Joseph Rubinfeld ,  Elliott L. Fineman

    IPC分类号： A61K9127

    CPC分类号： A61K31/5685 ,  A61K9/1272

    摘要： Liposome preparations which comprise a lipid, or lipid like compound and a 5&bgr; steroid, DHEA or an organic acid derivative of the 5&bgr; steroid or DHEA are described. The lipsome may also include an entraped aqueous portion which comprises dissolved therein the expression product of the ob gene. Methods for treating conditions including obesity,hypercorticoidism and diabetes using the liposome preparations are also claimed.

    摘要翻译： 描述了包含脂质或类脂类化合物和5beta类固醇，DHEA或5beta类固醇或DHEA的有机酸衍生物的脂质体制剂。 唇形体还可以包括含有水分的部分，其包含在其中溶解ob基因的表达产物。 还要求保护使用脂质体制剂治疗包括肥胖症，高皮质激素和糖尿病的病症的方法。

    Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
    4.
    发明授权
    Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation 有权

    公开(公告)号：US06613753B2

    公开(公告)日：2003-09-02

    申请号：US09790483

    申请日：2001-02-21

    申请人： Joseph Rubinfeld ,  Lucy Chang ,  Jorge DiMartino

    发明人： Joseph Rubinfeld ,  Lucy Chang ,  Jorge DiMartino

    IPC分类号： A01N4304

    CPC分类号： A61K31/495 ,  A61K31/00 ,  A61K31/57 ,  A61K39/39558 ,  A61K2300/00

    摘要： Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.

    Formulation of nitrogen mustard
    5.
    发明授权
    Formulation of nitrogen mustard 失效

    公开(公告)号：US06583125B2

    公开(公告)日：2003-06-24

    申请号：US09938473

    申请日：2001-08-23

    申请人： Joseph Rubinfeld

    发明人： Joseph Rubinfeld

    IPC分类号： A61K31715

    CPC分类号： B82Y5/00 ,  A61K47/6951

    摘要： Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.

    Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
    9.
    发明授权
    Sequential therapy comprising a 20(S)-camptothecin and an anthracycline 失效
    连续疗法包括20（S） - 喜树碱和蒽环类

    公开(公告)号：US06627614B1

    公开(公告)日：2003-09-30

    申请号：US10163520

    申请日：2002-06-05

    申请人： Joseph Rubinfeld

    发明人： Joseph Rubinfeld

    IPC分类号： A61K3170

    CPC分类号： A61K31/70 ,  A61K45/06

    摘要： A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation. The method comprises: administering to the patient an anthracycline for a period of time during which a 20(S)-camptothecin is not present in a pharmacologically active form in patient's blood; and administering a 20(S)-camptothecin to the patient.

    摘要翻译： 提供了一种治疗患有与不良或不受控制的细胞增殖相关的疾病的患者的方法。 该方法包括：向患者施用蒽环类药物，其中20（S） - 喜树碱在患者血液中不以药理学活性形式存在; 并向患者施用20（S） - 喜树碱。